Candriam SCA’s Vera Therapeutics VERA Stock Holding History

Candriam SCA’s Portfolio VERA Stock Details VERA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18.4M	Buy	568,560 +100,461	+21%	+$3.51M	0.08%	207
2026 Q2	$20.1M	Sell	468,099 -7,236	-2%	-$270K	0.09%	201
2026 Q1	$19.1M	Buy	475,335 +25,781	+6%	+$1.11M	0.1%	201
2025 Q4	$22.8M	Buy	449,554 +22,365	+5%	+$794K	0.11%	176
2025 Q3	$12.4M	Buy	427,189 +130,248	+44%	+$3.01M	0.07%	243
2025 Q2	$7M	Sell	296,941 -66,751	-18%	-$1.5M	0.04%	304
2025 Q1	$8.74M	Sell	363,692 -2,307	-0.6%	-$74.1K	0.05%	258
2024 Q4	$15.5M	Sell	365,999 -84,993	-19%	-$3.76M	0.09%	202
2024 Q3	$19.9M	Buy	450,992 +157,232	+54%	+$5.97M	0.11%	180
2024 Q2	$10.6M	Buy	293,760 +185,760	+172%	+$7.37M	0.06%	246
2024 Q1	$4.66M	Buy	+108,000	New	+$3.85M	0.03%	354

Other funds holding VERA

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

E. Ohman J:or Asset Management Stockholm, Sweden $4.47B AUM 27.58% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

J. Safra Sarasin Holding $7.05B AUM 26.14% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Candriam SCA's VERA Position: Q3 2026 in Review

Candriam SCA increased its Vera Therapeutics (VERA) stake by 21% in Q3 2026, buying an estimated $3.51M and bringing the position to 568,560 shares worth $18.4M. The position accounts for 0.08% of the portfolio, ranked #207.

Candriam SCA first reported a position in VERA in Q1 2024 and has held it in 11 quarters since. The position peaked at $22.8M in Q4 2025. 49 funds tracked by Wall St. Rank hold VERA as of Q3 2026.

Candriam SCA held 568,560 shares of Vera Therapeutics worth $18.4M as of Q3 2026.
Candriam SCA bought 100,461 Vera Therapeutics shares in Q3 2026, an estimated $3.51M.
Vera Therapeutics made up 0.08% of Candriam SCA's portfolio in Q3 2026, its #207 holding.
Candriam SCA first reported a position in Vera Therapeutics in Q1 2024 and has held it in 11 quarters since.
Candriam SCA's Vera Therapeutics position peaked at $22.8M in Q4 2025.
49 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.